# Beroe Inc.

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/beroe-inc
Canonical HTML page: https://getyourbrief.com/entity/beroe-inc

## Timeline

- **2029-08-01**: Tariff Escalates to 200% — The tariff rate doubles to 200% on generic drug imports.
- **2029-08-01**: Tariff Escalates to 200% — The tariff rate doubles to 200% on generic drug imports.
- **2028-08-01**: 100% Tariff Takes Effect — A 100% duty is imposed on eligible generic drug imports.
- **2028-08-01**: 100% Tariff Takes Effect — A 100% duty is imposed on eligible generic drug imports.
- **2026-08-01**: Duty‑Free Period Begins — Imported generics enter a two‑year duty‑free window.
- **2026-08-01**: Duty‑Free Period Begins — Imported generics enter a two‑year duty‑free window.
- **2026-07-21**: Generic Drug Tariff Schedule Announced — The President announces that generic drugs will remain duty‑free for two years, then face 100% (2028) and 200% (2029) tariffs under Section 232.
- **2026-07-21**: Generic Drug Tariff Schedule Announced — The President announces that generic drugs will remain duty‑free for two years, then face 100% (2028) and 200% (2029) tariffs under Section 232.
- **2026-04-02**: Executive Order Tariffs Patented Medicines — President Trump signs an order imposing 100% tariffs on imported patented drugs while exempting generics, biosimilars, and their ingredients.
- **2026-04-02**: Executive Order Tariffs Patented Medicines — President Trump signs an order imposing 100% tariffs on imported patented drugs while exempting generics, biosimilars, and their ingredients.

## Recent coverage (5 stories, network-wide)

### 100% Tariff on Generic Drugs: Market Disruption Looms as Profit Margins Vanish
2026-08-07 06:31:20 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The 100% then 200% tariffs on generic drugs represent a systemic risk to the U.S. generic pharmaceutical market. With margins already compressed and price pass-through blocked, investors should brace for product exits, consolidation, and potential supply chain disruptions that could raise overall healthcare costs.
Full story: https://getfinancebrief.com/story/finance-generic-drug-tariffs-market-impact

### Biosimilars Hit by Tariffs: 200% Duty by 2029 Threatens Biotech Outsourcing Models
2026-08-07 06:30:09 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The tariff escalation to 200% on generic drugs by August 2029 also applies to biosimilars, which were initially exempt. For biotech and pharma, this could disrupt outsourcing strategies and market access for follow-on biologics. The timeline analysis details product-level risks.
Full story: https://getbiobrief.com/story/biotech-pharma-generic-drug-tariffs-biosimilars

### 9 in 10 Prescriptions at Risk: Generic Drug Tariffs Could Fuel Patient Shortages by 2028
2026-08-07 06:29:00 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2

With generic drugs accounting for 90% of U.S. prescriptions, the 100% tariff scheduled for 2028 threatens to narrow supply, potentially causing shortages of essential medicines. Price caps and hospital discount programs prevent cost pass-through, leaving healthcare systems vulnerable.
Full story: https://gethealthbrief.com/story/healthcare-generic-drug-tariffs-patient-shortages

### 100% Tariff on Generics to Squeeze Supply: 3-5 Year Reshoring Gap Leaves U.S. Vulnerable
2026-08-07 06:27:48 · Sector: supply · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The impending 100% tariff on imported generic drugs could trigger widespread product discontinuations, as thin margins and pricing constraints block pass-through costs. With three to five years needed to build FDA-approved plants, supply chain disruptions are inevitable. The analysis explores manufacturing dependencies and risk exposure.
Full story: https://getsupplybrief.com/story/supply-chain-generic-drug-tariffs-reshoring-gap

### Generic Drug Tariffs: Section 232 Proclamation Void Leaves 100% Duty Effective Date in Limbo
2026-08-07 06:26:39 · Sector: legal · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The Trump administration’s generic drug tariff announcement raises critical legal questions. Without a Federal Register proclamation or annex of tariff lines, the impending 100% duty faces uncertainty under trade law. This analysis examines the Section 232 authority and the regulatory void affecting contracts and compliance.
Full story: https://getlegalbrief.com/story/generic-drug-tariffs-section-232-legal-limbo

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.